Company intelligence / Profile preview

Voyager Therapeutics

Cambridge or Lexington*, Massachusetts, United Statesvoyagertherapeutics.com ↗

Ownership: Public · VYGR
Employees: ~172
Development stage: Phase 1

Overview

Voyager Therapeutics has demonstrated robust preclinical results with its TRACER-derived AAV capsids enabling efficient CNS delivery after intravenous dosing. In non-human primate models, their tau-silencing program achieved significant reductions in tau mRNA and protein levels across the brain. The SOD1 ALS program also showed strong target engagement and safety in NHPs. Multiple programs are advancing toward IND filings in the next one to two years[4][7].

Therapeutic areas: Neurology
Modalities: Gene therapy (AAV-based)Vectorized antibodies (gene-delivered mAbs)RNAi/siRNA gene silencing
Industry: Biotech

Drug pipeline

25 assets

VY7523

24 more assets in the full pipeline.

Financials

Market cap: $106M
Total revenue: $40.4M
Enterprise value: $29.7M

Beyond the preview

Go deeper on Voyager Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Voyager Therapeutics.